Duke-NUS Graduate Medical School, 8 College Road, Singapore, 169857, Singapore.
Br J Dermatol. 2014 Jun;170(6):1319-26. doi: 10.1111/bjd.12806. Epub 2014 Apr 29.
Bullous pemphigoid (BP) is the most common autoimmune-mediated subepidermal blistering skin disease and is associated with significant morbidity and mortality.
To determine the 3-year mortality rate, risk factors and causes of death in patients with BP in Singapore, compared with the general population.
We conducted a retrospective cohort study of all newly diagnosed patients with BP seen at the National Skin Centre from 1 April 2004 to 31 December 2009. Demographic and clinical data on comorbidities and treatment were recorded. Mortality information was obtained from the National Registry of Diseases.
In total 359 patients were included in our study. The 1-, 2-, 3-year mortality rates were 26·7%, 38·4% and 45·7%, respectively. The 3-year standardized mortality risk for patients with BP was 2·74 (95% confidence interval 2·34-3·19) times higher than for the age- and sex-matched general population. Parkinson disease, heart failure and chronic renal disease were associated with increased mortality, while combination treatment with low-to-moderate-dose corticoste-roids and immunomodulatory agents such as doxycycline and/or nicotinamide was associated with lower mortality. Overall, infections were the most common cause of death (59·8%), with the main causes of death being pneumonia (42·7%), cardiovascular disease (14·6%) and stroke (11·6%).
This study confirms an increased 3-year mortality rate for patients with BP in Singapore. Risk factors for increased mortality include medical comorbidities, especially neurological, cardiac and renal diseases. Treatment with combination therapy, including the use of low-to-moderate-dose corticosteroid, appeared to decrease mortality risk in patients with BP.
大疱性类天疱疮(BP)是最常见的自身免疫性表皮下水疱性皮肤病,与显著的发病率和死亡率相关。
与普通人群相比,确定新加坡 BP 患者的 3 年死亡率、危险因素和死亡原因。
我们对 2004 年 4 月 1 日至 2009 年 12 月 31 日期间在国家皮肤中心新诊断为 BP 的所有患者进行了回顾性队列研究。记录了合并症和治疗的人口统计学和临床数据。死亡率信息从疾病登记处获得。
共纳入 359 例患者。1、2、3 年死亡率分别为 26.7%、38.4%和 45.7%。BP 患者的 3 年标准化死亡率风险是年龄和性别匹配的普通人群的 2.74 倍(95%置信区间 2.34-3.19)。帕金森病、心力衰竭和慢性肾病与死亡率增加相关,而低-中剂量皮质类固醇和免疫调节剂(如多西环素和/或烟酰胺)联合治疗与较低的死亡率相关。总体而言,感染是最常见的死亡原因(59.8%),主要死亡原因是肺炎(42.7%)、心血管疾病(14.6%)和中风(11.6%)。
本研究证实了新加坡 BP 患者的 3 年死亡率增加。增加死亡率的危险因素包括医疗合并症,特别是神经、心脏和肾脏疾病。联合治疗,包括使用低-中剂量皮质类固醇的治疗,似乎降低了 BP 患者的死亡风险。